The 2023-2028 Outlook for Biostimulants in India

This study covers the latent demand outlook for biostimulants across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biosimilars and Follow-on Biologics Drugs in India

This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each ci...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biosimilars in India

This study covers the latent demand outlook for biosimilars across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent sh...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biopreservation in India

This study covers the latent demand outlook for biopreservation across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percen...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Bioplastic Textiles in India

This study covers the latent demand outlook for bioplastic textiles across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the pe...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biophotonics in India

This study covers the latent demand outlook for biophotonics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent s...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biopesticides in India

This study covers the latent demand outlook for biopesticides across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biological Imaging Reagents in India

This study covers the latent demand outlook for biological imaging reagents across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Biologic Vasculitis Treatments in India

This study covers the latent demand outlook for biologic vasculitis treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in quest...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Bioinformatics Services in India

This study covers the latent demand outlook for bioinformatics services across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, th...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for biostimulants across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biostimulants. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biostimulants as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acadian Seaplants, ADAMA, Agricen, Agriculture Solutions, Inc., Agrinos, Agroenzymas, Artal Agronutrients, Arysta LifeSceince, Atlantica Agricola, ATLÁNTICA AGRICOLA, Barndt Consolidated, BASF, Bayer, BioAg Alliance, BioAtlantis, Biolchim, Biostadt India, Biovert-Manvert, Brandt Consoliated, Cairochem, Corp., Eastman Chemical Company, Evergrow, FMC Corporation, Goemar, Haifa Group, Humic Growth, Ilsa, Isagro, Italpollina, Kelp Products International, Koppert, Laboratoires Goemar, Lallemand, LLSA, Micromix, Novozymes, OMEX, Platform Specialty Product, Premier Tech, SAPEC, Seipasa, Syngenta, Taminco, The DOW Chemical Company, Trade Corporation International, Tradeecorp Internationals, UPI, UPL, Valagro, and West Coast Marine Bio-Processing. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biosimilars and follow-on biologics drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biosimilars and follow-on biologics drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Allozyne, Alteogen, Alvogen, Amarey Novamedical, AMEGA Biotech, Amgen, Apotex, Astellas Pharma, AstraZeneca, Avesthagen, Baxter, Bayer, Beijing Four Rings, BIOCAD, Bioceuticals, Biocon, Biogen, Biolab, Bionovis, Biopartners, Biosidus, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Cambridge Antibody Technology, CCL Pharmaceuticals, CCM Duopharma, Celltrion, Centocor Ortho Biotech, Chong Kun Dang, Chugai, CinnaGen., Coherus BioSciences, Compass Biotechnologies, Cristália, CT Arzneimittel, Cyplasin, Daiichi Sankyo, Dong-A Pharmaceutical, Dr. Reddy’s Laboratories, Egis Pharmaceuticals, Eisai, Eli Lilly, Elpen Pharmaceutical, Emcure Pharmaceuticals, EMS, Epirus, Eurofarma, Express Scripts, FibroGen, Finox Biotech, Fuji Pharma, Gan & Lee, Genetech, Genexine, Gennova, GenSci, Genzyme, Geropharm, Gilead Sciences, GlaxoSmithKline, Hangzhou Jiuyuan Gene Engineering Company, Hanmi Pharmaceutical, Hanwha Chemical, Haselmeier, Health Canada, Helius Biotech, Hexal, Hindustan Antibiotic, Hospira, Hualida Biotech, Hypermarcas, IGES Institute, Intas Biopharmaceuticals, inVentiv Health, JCR Pharmaceuticals, Johnson & Johnson, Kabi, Kemwell Biopharma, Kissea, Koçak Farma, Kwizda Pharma, Kyowa Hakko Kirin, Landsteiner Scientific, LG Life Sciences, Libbs, LKM SA, Lonza Group, Mabion, Marvel Life Sciences, MEDICE Arzneimittel Pütter, Merck (MSD), Minapharm, Mitsubishi Tanabe, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mycenax Biotech, Mylan, Nichi-Iko, Nippion Kayaku, Novartis, Novo Nordisk, Nuron Biotech, Oncobiologics, Ortho Pharmaceutical, Orygen, PanGen Biotech, Pfenex, Pfizer, Pharmapark, Pharmstandard, PRA International, Pro Generika, Qilu Pharmaceutical, Quintiles, Ranbaxy Laboratories, RAND Corporation, Ratiopharm, Regeneron Pharmaceuticals, Reliance GeneMedix, Rentschler Biotechnologie, Roche, Samsung Bioepis, Sandoz, Sanofi, SciGen, Shandong Kexing Pharma, Shanghai Celgen Biopharmaceutical, Shantha Biotechnics, Shinogi, Sicor Biotech, Sothema Laboratories, Spectrum Pharmaceuticals, Stada Arzneimittel, Stragen Pharma, Strides Arcolab, Syngene International, Synthon Biopharmaceuticals, Takeda, Teva, Tianjin Hualida Biotechnology, Tonghua Dongbao, TSH Biopharm, União Química, USV Biologics, Virchow Biotech, Wanbang Biopharmaceuticals, Wockhardt, Xiamen Amoytop Biotech, Zenotech, Zhejian Huahai Pharmaceutical, Zuventus, and Zydus Biovation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biosimilars across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biosimilars. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biosimilars as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3S Bio, AbbVie, Allergan, AMEGA Biotech, Amgen, Apotex, BIOCAD, Biocon, Biogen, Biopartners, Bioton, Boehringer Ingelheim, Celltrion, Cinnagen, Coherus BioSciences, DM Bio, Dr. Reddy`s Laboratories, Eli Lilly, Emcure Pharmaceuticals, EMD Serono, F. Hoffmann-La Roche, Fresenius Kabi, Fujifilm Diosynth Biotechnologies, Gedeon Richter, Genentech, Green Cross, Hanwa Chemical Corporation, Hospira, Intas Pharmaceuticals, JHL Biotech, LG Life Sciences, Mabxience, Merck, Mylan, Nanogen Biopharmaceutical, Neuclone, Novartis, Pfenex, Pfizer, Probiomed, RATIOPHARM GmbH, Roche Diagnostics, Samsung Bioepis, Sandoz, Shanghai Fosun Pharmaceutical, Stada Arzneimittel, Synthon Pharmaceuticals, Tanvex Biopharma, Teva Pharmaceutical Industries, and WOCKHARDT.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biopreservation across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biopreservation. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biopreservation as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AMS BIOTECHNOLOGY (AMSBIO), Arctiko, Atlanta Biologicals, Avantor, BioCision, Biogenics, BioLife Solutions, BioLifeSolutions, Biomatrica, Bio-Techne, Cesca Therapeutics, Chart Industries, Core Dynamics, Ltd., Custom Biogenic Systems, Exact Sciences, Genzyme, Helmer Scientific, Labvantage Solutions, Lifeline Scientific, Merck KGaA, OPS Diagnostics, Organ Recovery Systems, Panasonic Corporation, PHC Holdings, Princeton CryoTech, Qiagen, SHANGHAI GENEXT Medical Technology Company, Ltd., Sigma, So-Low Environmental Equipment Company, STEMCELL Technologies, Taylor-Wharton, Teva Pharmaceuticals, Thermo Fisher Scientific, VWR, and Worthington Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for bioplastic textiles across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for bioplastic textiles. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of bioplastic textiles as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include BASF, DuPont de Nemours, Ercros, FKuR Biome Bioplastics, NaturePlast, and Natureworks. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biophotonics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biophotonics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biophotonics as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Affymetrix, Andor Technology, BD (Becton, Dickinson and Company), Becton, BioTek Instruments, Carl Zeiss, Dickinson and Company, FEI Company, Hamamatsu Photonics, IDEX, IPG Photonics, Lumenis, Ocean Optics, Olympus America, Oxford Instruments, PerkinElmer, Toshiba, and Zecotek Photonic, Inc.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biopesticides across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biopesticides. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biopesticides as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 1,4Group, Inc. (USA), Actagro LLC., Adjuvants Plus Inc (Canada), AG Biochem, Agraquest, Agrauxine, AGRICHEM, Albaugh, American Vanguard, Amit Biotech, AMVAC Chemical, Andermatt Biocontrol, Arbico Organics, Arysta Lifescience, BASF, Bayer, Becker Underwood, Biobest Group, BioConsortia,, Inc., BIOFA, BIONEMA, Bio-Tech, Ltd., Bioworks, Camson Bio Technologies, Certis Europe, Certris Europe, Corteva Agriscience, Cropex Pvt, Ltd., De Sangosse S.A.S., Dow AgroSciences, DuPont, Eagle Plant Protect Private, Emery Oleochemicals, Envera, Environmental Crop Management, Excel Crop Care, FMC Corporation, FUTURECO BIOSCIENCE, Geolife Group, Gujarat State Fertilizers & Chemicals, International Panaacea, Invivo, Isagro, Ishihara Sangyo Kaisha, Kilpest India, Ltd., Kimitech Group, Kopert Biological System, Koppert, Lallemand, LAM International, Marrone Bio Innovation, Monsanto, Nav Agro Pvt, Ltd., Novozyme Biologicals, Nufarm, ORO AGRI, Parry America, Real IPM UK, Rolfes Agri, Sikko Industries, SOM PHYTOPHARMA India, Ltd., SSC, stk bio-ag technologies, STOCKTON BIO-AG Technologies, Stoller, Sumitomo Chemical India Pvt, Ltd., Syngenta, T.Stanes Company, Ltd., Trifolio-M, UPL, Valent BioScience Corporation, VEGALAB SA, and W. Neudorff GmbH. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biological imaging reagents across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biological imaging reagents. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biological imaging reagents as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Becton, Dickinson and Company, Bracco, GE Healthcare, Guerbet, Lantheus Holdings, Luminex Corporation, PerkinElmer, Siemens Healthineers, and Thermo Fisher Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for biologic vasculitis treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for biologic vasculitis treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biologic vasculitis treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AB Science, Acorda Therapeutics, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter International, Boehringer Ingelheim International, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene Corporation, Celltrion Healthcare Company, Coherus BioSciences, Daiichi Sankyo Company, Eisai Company, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline, Hospira, Idera Pharmaceuticals, Immunomedics, Incyte, Lexicon Pharmaceuticals, MedImmune, Merck & Company, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz International, Sanofi, Takeda Pharmaceutical Company, UCB, and Vertex Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for bioinformatics services across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for bioinformatics services. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of bioinformatics services as including all commonly understood services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Accelrys, Affymetrix, Affymretrix, Inc., Agilent Technologies, Baseclear, BGI, Biomatters Geneious, Biomax Informatics, Biovia (Accelrys Inc), Bruker Daltonics, CD Genomics, CLC bio, Creative-Biolabs, DNAnexus, DNASTAR, Eurofins Scientific, FIOS Genomics, Gene Code Corporation, GENEWIZ, GSL Biotech LLC (SnapGene), GVK Biosciences, IBM Life Sciences, Illumina, Life Technologies, Macrogen, Medgenome Labs, Microsynth, Neogenomics, Non Linear Dynamics., Nxt-Dx, PerkinElmer, Premier Biosoft, Qiagen, Source BioScience, Strand Life Sciences, Inc., and Thermo Fisher Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT